Oncology News

Recently published data showed an association between nucleos(t)ide analogue therapy for chronic hepatitis B virus and a reduced risk for intrahepatic cholangiocarcinoma.

A recently published analysis of veterans with hepatocellular carcinoma showed that receipt of liver transplantation, Barcelona Clinic Liver Cancer stage and multidisciplinary tumor board correlated with higher 3-year health care costs but increased survival time.

Mexican-American individuals residing in the United States had more risk factors for liver cancer than their counterparts living in Mexico, according to study results presented at American Association for Cancer Research Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved.

Among patients with cirrhosis, muscle volume loss and hepatocellular carcinoma within Milan criteria were prognostic factors for mortality, according to recently published data.

The FDA approved nivolumab for the treatment of patients with hepatocellular carcinoma who underwent prior therapy with sorafenib.

Patients with hepatocellular carcinoma who started Nexavar therapy at reduced dosages had a lower total cumulative pill cost and were less likely to discontinue due to adverse effects, according to recently published data. Additionally, lower starting doses did not affect overall survival.

Dietary exposure to aflatoxin, or toxins produced by fungi affecting certain crops, may increase the risk for gallbladder cancer, according to new research.

Among U.S. veterans with hepatitis B, researchers found that the risk for hepatocellular carcinoma was higher among Asian-Pacific Islanders than Caucasians and African-Americans, increased with the presence of cirrhosis, and significantly increased among those without cirrhosis after age 40 regardless of race.

In a cohort of patients with chronic hepatitis B without cirrhosis, the risk for hepatocellular carcinoma was significantly higher among those with a FIB-4 index over 1.29, according to recently published data.

The FDA recently granted two orphan drug designations to Lion TCR for T-cell therapy products for the treatment of hepatocellular carcinoma, according to a press release.